(-)-Stepholidine promotes proliferation and neuronal differentiation of rat embryonic striatal precursor cells in vitro.
The present study investigated the influence of (-)-stepholidine, an effective dopamine D1 receptor agonist and D2 receptor antagonist, on the development of neural precursor cells. Incubation of striatal neural precursor cells with stepholidine resulted in significant increase in the number of proliferating precursor cell spheres when in the presence of fibroblast growth factor-2. This action can be blocked by application of haloperidol. Treatment with stepholidine also increased the number of microtubule-associated protein-2-immunoreactive cells in the cultures and promoted marked increases in tyrosine hydroxylase expression. These findings suggest that stepholidine is involved in the regulation of proliferation of precursor cells. The effect appears to be mediated by dopamine receptors. Stepholidine also promotes the differentiation of precursor cells, however, this action may be independent of its effect on dopaminergic receptors.
Guo
Hong
H
Key Laboratory of Proteomics, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yueyang Road, 200031, P. R. China.
Yu
Yi
Y
Xing
Lei
L
Jin
Guo-Zhang
GZ
Zhou
Jiawei
J
D000818:Animals; D001599:Berberine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism / Q000494:pharmacology; D018929:Cell Culture Techniques; D002454:Cell Differentiation / Q000187:drug effects; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D018491:Dopamine Agonists / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology*; D065127:Dopamine D2 Receptor Antagonists; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D006220:Haloperidol / Q000494:pharmacology; D007150:Immunohistochemistry; D008869:Microtubule-Associated Proteins / Q000378:metabolism; D008938:Mitosis / Q000187:drug effects; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011954:Receptors, Dopamine / Q000187:drug effects* / Q000378:metabolism*; D017447:Receptors, Dopamine D1 / Q000819:agonists / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013234:Stem Cells / Q000187:drug effects* / Q000378:metabolism; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D019208:Brain-Derived Neurotrophic Factor; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D008869:Microtubule-Associated Proteins; D012333:RNA, Messenger; D011954:Receptors, Dopamine; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D001599:Berberine; C010513:stepholidine; D016222:Fibroblast Growth Factor 2; D014446:Tyrosine 3-Monooxygenase; D006220:Haloperidol